Terms: = Breast cancer AND FOXO3, FKHRL1, 2309, ENSG00000118689, MGC31925, MGC12739, FOXO2, FOXO3A, O43524, AF6q21, FKHRL1P2, DKFZp781A0677 AND Clinical Outcome
4 results:
1. The Pan-cancer Multi-Omics Landscape of FOXO Family Relevant to clinical outcome and Drug Resistance.
Xie J; Zhang J; Tian W; Zou Y; Tang Y; Zheng S; Wong CW; Deng X; Wu S; Chen J; Mo Y; Xie X
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555288
[TBL] [Abstract] [Full Text] [Related]
2. foxo3A-induced LINC00926 suppresses breast tumor growth and metastasis through inhibition of PGK1-mediated Warburg effect.
Chu Z; Huo N; Zhu X; Liu H; Cong R; Ma L; Kang X; Xue C; Li J; Li Q; You H; Zhang Q; Xu X
Mol Ther; 2021 Sep; 29(9):2737-2753. PubMed ID: 33940159
[TBL] [Abstract] [Full Text] [Related]
3. foxo3a Mediates the Inhibitory Effects of the Antiepileptic Drug Lamotrigine on breast cancer Growth.
Pellegrino M; Rizza P; Nigro A; Ceraldi R; Ricci E; Perrotta I; Aquila S; Lanzino M; Andò S; Morelli C; Sisci D
Mol Cancer Res; 2018 Jun; 16(6):923-934. PubMed ID: 29523760
[TBL] [Abstract] [Full Text] [Related]
4. Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer.
Li H; Liu L; Chang H; Zou Z; Xing D
Cell Death Dis; 2018 Jan; 9(2):137. PubMed ID: 29374168
[TBL] [Abstract] [Full Text] [Related]
